France recalls rare disease drug Tavneos after deaths
· Medical Xpressedited by Andrew Zinin
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process
Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
reputable news agency
proofread
The GIST Add as preferred source
A drug called Tavneos, used to treat rare autoimmune diseases, will be pulled from shelves in France, the country's medicine watchdog said Wednesday, after it was linked to 20 deaths in Japan.
"The recall of all batches available in France will begin on August 19," France's medicine safety agency ANSM said in a statement.
The agency noted that the European Commission revoked the drug's marketing authorization earlier this month because "the benefits are no longer proven to outweigh its risks."
Tavneos is made by the U.S. biotech firm Amgen and is sold by different partner pharmaceutical companies around the world.
It is used to treat adults with severe and rare autoimmune diseases that cause inflammation of the blood vessels.
Kissei Pharmaceutical, which sells the drug in Japan, said in May that 20 deaths had been reported among people using it since 2022.
The company warned doctors of "the risk of severe liver dysfunction" and asked them to stop prescribing it.
Both Kissei and Amgen said the deaths included cases for which no causal link to the medicine could be determined.
But the warning raised doubts about the rigor of the study submitted to various regulatory authorities to determine whether it should be authorized for sale.
The European Medicines Agency reassessed the data and recommended in July that the drug be stripped of its market authorization.
The European Commission endorsed that recommendation earlier this month.
In France, the drug is prescribed to 600 patients, according to the ANSM.
"Abruptly stopping Tavneos without switching to an alternative should be avoided to prevent the condition from worsening," the agency warned, advising patients to consult a doctor about alternatives.
In the United States, the Food and Drug Administration offered Amgen the option of voluntarily withdrawing Tavneos from shelves.
But the company refused, so a procedure is underway to determine whether it will be forced to pull the drug.
Key medical concepts
Clinical categories
Clinical pharmacologyRheumatology Who's behind this story?
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 AFP
Citation: France recalls rare disease drug Tavneos after deaths (2026, August 19) retrieved 20 August 2026 from https://medicalxpress.com/news/2026-08-france-recalls-rare-disease-drug.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.